Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Board expanded to seven directors, adding independent Class II director Robert Azelby through the 2029 annual meeting.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to seven directors, adding independent Class II director Robert Azelby through the 2029 annual meeting
- Azelby joins Compensation and Nominating and Corporate Governance committees, strengthening board oversight
- New-director equity package: option for 35,910 shares at $27.97 plus 5,740 RSUs
- Annual cash retainers total $57,500 for Board, Compensation Committee and NCG Committee service
- Vesting over three years ties Azelby’s equity incentives to continued board service
Item EX-99.1 · Exhibit EX-99.1
- Board appointment of Robert Azelby adds oncology commercialization and late-stage drug-development expertise
- Appointment aligns with Tango’s effort to advance vopimetostat toward potential late-stage development
- Vopimetostat targets MTAP-deleted cancers, affecting 10–15% of human cancers
- MTAP deletions occur in approximately 40% of pancreatic cancer and 15% of lung cancer
- No compensation, committee assignment or governance-rights terms disclosed in the exhibit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.